Lite Strategy, Inc. reports developments around a Litecoin-focused digital asset treasury strategy, with Litecoin (LTC) designated as its primary treasury reserve asset. News from LITS centers on fiscal results, active treasury operations, covered-call use on LTC holdings, capital allocation, and the company’s common stock repurchase authorization.
The company’s recent corporate history includes its rebrand from MEI Pharma, Inc. and Nasdaq ticker change from MEIP to LITS. Updates also reference the company’s transition away from its prior pharmaceutical profile, including the sale of the ME-344 clinical asset, and its disclosures around treasury strategy execution and governance.
Lite Strategy (NASDAQ: LITS) marked the 14th anniversary of Litecoin on October 16, 2025, highlighting Litecoin’s longevity as the second-longest-running blockchain and its transaction history.
Lite Strategy says it is the first U.S.-listed public company to adopt Litecoin as its primary reserve asset, positioning LITS as a regulated, public-market vehicle for institutional exposure to Litecoin. Management frames the move as an immediate alternative while some digital asset ETFs remain pending amid an ongoing government shutdown.
MEI Pharma (NASDAQ:MEIP) announced its corporate rebranding to Lite Strategy, Inc. and will change its ticker to LITS effective September 11, 2025. The transformation reflects the company's strategic pivot to digital asset treasury management, focusing on Litecoin (LTC) as its primary reserve asset.
The company has already secured over $100 million in LTC with guidance from Litecoin creator Charlie Lee, who serves on the board, and GSR Ventures. While embracing this new direction, Lite Strategy continues to maintain its pharmaceutical pipeline, evaluating development opportunities for voruciclib and zandelisib.